Crystalline materials of...

Details Crystalline materials of... Crystalline materials of...

2009-05-19

2010-11-09

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

active

07829711

ABSTRACT:
The instant invention provides crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione; processes for the production of such crystalline materials; pharmaceutical compositions comprising such crystalline materials; and methods of treating HIV or AIDS with such crystalline materials or such pharmaceutical compositions.

REFERENCES:
patent: 3135794 (1964-06-01), Archer
patent: 4791104 (1988-12-01), Picciola et al.
patent: 5023265 (1991-06-01), Scherlock et al.
patent: 5124327 (1992-06-01), Greenlee et al.
patent: 5192770 (1993-03-01), Clark et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 5811432 (1998-09-01), Marfat et al.
patent: 6008231 (1999-12-01), Lebaut et al.
patent: 6172085 (2001-01-01), Ohkawa et al.
patent: 6232327 (2001-05-01), Nickel et al.
patent: 6469006 (2002-10-01), Blair et al.
patent: 6476034 (2002-11-01), Wang et al.
patent: 6573262 (2003-06-01), Wallace et al.
patent: 6632819 (2003-10-01), Wang et al.
patent: 6825201 (2004-11-01), Wang et al.
patent: 6900206 (2005-05-01), Kadow et al.
patent: 7037913 (2006-05-01), Wang et al.
patent: 7087610 (2006-08-01), Wang et al.
patent: 7183284 (2007-02-01), Kadow et al.
patent: 7348337 (2008-03-01), Wang et al.
patent: 7354924 (2008-04-01), Wang et al.
patent: 7396830 (2008-07-01), Wang et al.
patent: 7449476 (2008-11-01), Ruediger et al.
patent: 7501419 (2009-03-01), Bachand et al.
patent: 7504399 (2009-03-01), Wang et al.
patent: 7572810 (2009-08-01), Wang et al.
patent: 2002/0061892 (2002-05-01), Wang et al.
patent: 2003/0069266 (2003-04-01), Wang et al.
patent: 2003/0207910 (2003-11-01), Wang et al.
patent: 2003/0236277 (2003-12-01), Kadow et al.
patent: 2004/0063744 (2004-04-01), Wang et al.
patent: 2004/0063746 (2004-04-01), Regueiro-Ren et al.
patent: 2004/0110785 (2004-06-01), Wang et al.
patent: 2005/0075364 (2005-04-01), Yeung et al.
patent: 2005/0124623 (2005-06-01), Bender et al.
patent: 2005/0209246 (2005-09-01), Ueda et al.
patent: 2005/0215543 (2005-09-01), Lin et al.
patent: 2005/0215544 (2005-09-01), Lin et al.
patent: 2005/0215545 (2005-09-01), Lin et al.
patent: 2006/0100209 (2006-05-01), Gu et al.
patent: 2006/0100432 (2006-05-01), Matiskella et al.
patent: 2007/0249579 (2007-10-01), Wang et al.
patent: 0379314 (1990-07-01), None
patent: 0484071 (1992-05-01), None
patent: 0530907 (1993-03-01), None
patent: 1069111 (2001-01-01), None
patent: WO 93/01181 (1993-01-01), None
patent: WO 95/04742 (1995-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 97/24350 (1997-07-01), None
patent: WO 98/28292 (1998-07-01), None
patent: WO 99/24065 (1999-05-01), None
patent: WO 00/00201 (2000-01-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/51984 (2000-09-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 00/76521 (2000-12-01), None
patent: WO 01/22954 (2001-04-01), None
patent: WO 01/62255 (2001-08-01), None
patent: WO 02/04440 (2002-01-01), None
patent: WO 02/10152 (2002-02-01), None
patent: WO 02/62423 (2002-08-01), None
patent: WO 02/085301 (2002-10-01), None
patent: WO 03/041644 (2003-05-01), None
patent: WO 03/068221 (2003-08-01), None
patent: WO 03/082881 (2003-10-01), None
patent: WO 03/092695 (2003-11-01), None
patent: WO 03/103607 (2003-12-01), None
patent: WO 04/000210 (2003-12-01), None
patent: WO 2004/011425 (2004-02-01), None
patent: WO 2004/043337 (2004-05-01), None
patent: WO 2005/016344 (2005-02-01), None
patent: WO 2005/121094 (2005-12-01), None
Heimbach, et al, “Absorption Rate Limit Considerations for Oral Phosphate Prodrugs,” Pharmaceutical Research, 20(6), pp. 848-856, 2003.
Stella, et al, Pharmacokinetics of Drug Targeting: Specific Implications for Targeting Via Prodrugs, Handbook of Experimental Pharmacology, Chapter 4, pp. 71-103, 1991.
Zhu, et al, “A One-Pot Synthesis of Nitrogen-Containing Heteroaryl α-Keto Amides from Heteroaryl Halides,” Tetrahedron Letters, 46(20), pp. 3587-3589, 2005.
Yin, et al., “Simulated PXRD Patterns in Studies of the Phase Composition and Thermal Behavior of Bulk Crystalline Solids,” American Pharmaceutical Review, 2003, 6, 2, pp. 80-85.
Hotoda, “Small-Molecule Inhibitors of HIV-1 Entry Via Chemokine Receptors,” Drugs of the Future, 24(12), pp. 1355-1362, 1999.
Sodroski, “HIV-1 Entry Inhibitors in the Side Pocket,” Cell, 9, pp. 243-246, 1999.
Blair, et al, “HIV-1 Entry-An Expanding Portal for Drug Discovery,” Drug Discovery Today, 5(5), pp. 183-194, 2000.
Font, et al, “Indoles and Pyridazinol[4,5-b]Indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase,” Eur. J. Med. Chem., 30, pp. 963-971, 1995.
Romero, et al, J. Med. Chem., 36, pp. 1505-1508, 1993.
Young, et al, “2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase,” Bioorg. Med. Chem. Lett., 5(5), pp. 491-496, 1995.
Genin, et al, “Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs,” J. Med. Chem., 39, pp. 5267-5275, 1996.
Silvestri, et al, Antiviral Chem. Chemother., 9, pp. 139-148, 1998.
Fredenhagen, et al, “Semicochliodinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinease Related to Asterriquinones Produced by the Fungus Chrysosporium Merdarium,” J. of Antibiotics, 50, pp. 395-401, 1997.
Wang, et al., Org. Biol. Chem., 2005, 3, pp. 1781-1786.
Meanwelt et al., Current Opinion in Drug Discovery and Development, 2003, 6, 4, pp. 451-461.
Dueweke, et al, “The Binding of a Novel Bisheteroarylpiperazine Mediates Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase,” J. Biol. Chem., 267(1), pp. 27-30, 1992.
Dueweke, et al, “U-90152, a Potent Inhibitor of Human Immunodeficiency Virus Type 1 Replication,” Antimicrob. Agent, Chemother., 37(5), pp. 1127-1131, 1993.
Kato, et al, “New 5-HT3(Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives,” Chem. Pharm. Bull., 43(8), pp. 1351-1357, 1995.
Levacher, et al, “Broadening in the Scope of NADH Models by Using Chiral and Non Chiral Pyrroto [2,3-b]Pyridine Derivatives,” Tetrahedron, 47(3), pp. 429-440, 1991.
Resnyanskaya, et al, “A Simple Synthesis of 1-Acyl-3-Ary1-3H-Pyrrolo[2′,3′:4,5]Pyrimido[6,1-b]Benzothiazol-6-ium-2-olates: Betainic Derivates of a Novel Heterocyclic System,” Synthesis, 18, pp. 2717-2724, 2002.

Affiliated with

Also associated with

Rating

Crystalline materials of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline materials of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline materials of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4236596